AIDP will distribute Kappa Bioscience’s patented vitamin K2 MK-7 Ingredient, K2Vital, to the U.S. dietary supplements market.
Ingredients distributor AIDP (City of Industry, CA) has signed an agreement with vitamin K2 supplier Kappa Bioscience (Oslo, Norway) to distribute Kappa’s patented vitamin K2 MK-7 ingredient, K2Vital, to the U.S. dietary supplements market.
According to AIDP, vitamin K2 MK-7 is “the fastest growing vitamin worldwide and appears to be on track to become the next [vitamin] D3 due to its established bone- and heart-health benefits.”
In a press statement from AIDP, the company said that the agreement will help to fill a gap in the company’s ingredient portfolio. Mark Thurston, president, AIDP, stated in the press release that the partnership “further advances the collaboration we have enjoyed in Europe with K2Vital, now combined with our KoAct, collagen, Vantec D3, and calcium bone-health products.”
Egil Greve, CEO of Kappa Bioscience, added: “AIDP was selected after a thorough evaluation of companies who could best represent our proprietary ingredients in the U.S. market.”
Vitamin K2 MK-7 exerts its bone- and-heart-health benefits by activating the key proteins that bind calcium to bone and directing free calcium away from the arteries, thus helping to maintain healthy circulation, AIDP said.
Xsto Solutions (Morristown, NJ) will also continue to distribute K2Vital in the U.S.